These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 12810351)

  • 1. Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease.
    Stadnicki A; Mazurek U; Plewka D; Wilczok T
    Int Immunopharmacol; 2003 Jul; 3(7):939-44. PubMed ID: 12810351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease.
    Stadnicki A; Mazurek U; Gonciarz M; Plewka D; Nowaczyk G; Orchel J; Pastucha E; Plewka A; Wilczok T; Colman RW
    Dig Dis Sci; 2003 Mar; 48(3):615-23. PubMed ID: 12757180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation.
    Devani M; Vecchi M; Ferrero S; Avesani EC; Arizzi C; Chao L; Colman RW; Cugno M
    Dig Liver Dis; 2005 Sep; 37(9):665-73. PubMed ID: 15949977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of direct tissue isoelectric focused protein profiles of resected intestinal mucosa and endoscopic biopsies from patients with inflammatory bowel disease.
    Szewczuk MR; Depew WT
    Clin Invest Med; 1992 Feb; 15(1):49-59. PubMed ID: 1374000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
    Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease.
    Autschbach F; Giese T; Gassler N; Sido B; Heuschen G; Heuschen U; Zuna I; Schulz P; Weckauf H; Berger I; Otto HF; Meuer SC
    Virchows Arch; 2002 Nov; 441(5):500-13. PubMed ID: 12447682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers.
    Devani M; Cugno M; Vecchi M; Ferrero S; Di Berardino F; Avesani EC; de Franchis R; Colman RW
    Am J Gastroenterol; 2002 Aug; 97(8):2026-32. PubMed ID: 12190172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of chemokines (MDC, TARC) expression in mucosa from Crohn's disease and ulcerative colitis.
    Jugde F; Alizadeh M; Boissier C; Chantry D; Siproudhis L; Corbinais S; Quelvennec E; Dyard F; Campion JP; Gosselin M; Bretagne JF; Sémana G; Heresbach D
    Eur Cytokine Netw; 2001; 12(3):468-77. PubMed ID: 11566628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine.
    Klebl FH; Olsen JE; Jain S; Doe WF
    J Pathol; 2001 Dec; 195(5):609-15. PubMed ID: 11745698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease.
    Foell D; Wittkowski H; Ren Z; Turton J; Pang G; Daebritz J; Ehrchen J; Heidemann J; Borody T; Roth J; Clancy R
    J Pathol; 2008 Oct; 216(2):183-92. PubMed ID: 18729068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5'-aminosalicylate treatment.
    Siddique I; Hasan F; Khan I
    Scand J Gastroenterol; 2009; 44(1):56-64. PubMed ID: 18785066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the fragile histidine triad (FHIT) gene in inflammatory bowel disease.
    Wierzbicki PM; Adrych K; Kartanowicz D; Wypych J; Stanislawowski M; Zwolinska-Wcislo M; Celinski K; Skrodzka D; Godlewski J; Korybalski B; Smoczynski M; Kmiec Z
    J Physiol Pharmacol; 2009 Oct; 60 Suppl 4():57-62. PubMed ID: 20083852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase.
    Akazawa A; Sakaida I; Higaki S; Kubo Y; Uchida K; Okita K
    J Gastroenterol; 2002; 37(5):345-53. PubMed ID: 12051533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Annexin A2 expression in intestinal mucosa of patients with inflammatory bowel disease and its clinical implications].
    Zhang Z; Zhao X; Lv C; Li C; Zhi F
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Nov; 32(11):1548-52. PubMed ID: 23174572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substance P receptor expression in patients with inflammatory bowel disease. Determination by three different techniques, i.e., storage phosphor autoradiography, RT-PCR and immunohistochemistry.
    ter Beek WP; Biemond I; Muller ES; van den Berg M; Lamers CB
    Neuropeptides; 2007 Oct; 41(5):301-6. PubMed ID: 17602742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease.
    Shkoda A; Werner T; Daniel H; Gunckel M; Rogler G; Haller D
    J Proteome Res; 2007 Mar; 6(3):1114-25. PubMed ID: 17330946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease.
    Sawa Y; Oshitani N; Adachi K; Higuchi K; Matsumoto T; Arakawa T
    Int J Mol Med; 2003 Feb; 11(2):175-9. PubMed ID: 12525873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of VEGF and CD146 in patients with inflammatory bowel disease.
    Tsiolakidou G; Koutroubakis IE; Tzardi M; Kouroumalis EA
    Dig Liver Dis; 2008 Aug; 40(8):673-9. PubMed ID: 18374637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients.
    Wojtal KA; Eloranta JJ; Hruz P; Gutmann H; Drewe J; Staumann A; Beglinger C; Fried M; Kullak-Ublick GA; Vavricka SR
    Drug Metab Dispos; 2009 Sep; 37(9):1871-7. PubMed ID: 19487253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease.
    Vitali R; Stronati L; Negroni A; Di Nardo G; Pierdomenico M; del Giudice E; Rossi P; Cucchiara S
    Am J Gastroenterol; 2011 Nov; 106(11):2029-40. PubMed ID: 21788990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.